We previously found that p53 inhibits the important NADPH producer glucose-6-phosphate dehydrogenase (G6PD)^[@R4]^. As this did not fully explain the effect of p53 on NADPH, we investigated whether p53 controls expression of MEs, which catalyze the oxidative decarboxylation of malate to generate pyruvate and either NADPH or NADH^[@R5],[@R6]^ ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). In mammalian cells three ME isoforms have been identified: a cytosolic NADP^+^-dependent isoform (ME1), a mitochondrial NAD(P)^+^-dependent isoform (ME2), and a mitochondrial NADP^+^-dependent isoform (ME3), with ME1 and ME2 are the major isoforms ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"})^[@R7]^. By recycling the TCA cycle intermediate malate into the common TCA cycle carbon source pyruvate, MEs may have a regulatory role in matching TCA flux to cellular demand for energy, reducing equivalents, and biosynthetic precursors ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}).

We knocked down *p53* in human osteosarcoma U2OS cells and normal diploid fibroblast IMR90 cells using small hairpin (sh) RNA. This led to a significant increase in mRNA levels of *ME1* and *ME2* ([Fig. 1a, b](#F1){ref-type="fig"} and [Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}), accompanied by elevated protein levels and total enzymatic activity of ME1 and ME2 ([Fig. 1a, c](#F1){ref-type="fig"} and [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). Likewise, expression of ME1 and ME2 were substantially higher in p53 knockout (*p53^−/−^*) mouse embryonic fibroblasts (MEFs) compared to p53-wild-type (*p53^+/+^*) MEFs ([Fig. 1d](#F1){ref-type="fig"}). The normally short-lived p53 protein is stabilized by DNA damage signals. Cells treated with the genotoxic agents etoposide (ETO) and doxorubicin (DOX) showed both time- and concentration-dependent reductions in the expression of ME1 and ME2 ([Fig. 1e](#F1){ref-type="fig"} and [Supplementary Fig. 2b, d--f](#SD1){ref-type="supplementary-material"}). When *p53* was knocked down, the expression of ME1 and ME2 no longer responded to DNA damage ([Fig. 1e](#F1){ref-type="fig"}). These results demonstrate that the expression of ME1 and ME2 is controlled by p53 both at basal levels and when p53 is stabilized by DNA damage signals.

By analyzing the *ME* gene sequences, we identified a putative p53 response element (RE)^[@R8]^ in the first intron of the *ME1* gene (ME1-RE) and three putative REs in the first intron of the *ME2* gene (ME2-RE1 to ME2-RE3) ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Chromatin immunoprecipitation (ChIP) assays revealed that p53 bound to the genomic regions of the ME1-RE, ME2-RE1, and ME2-RE3, but not ME2-RE2. This binding was further enhanced when p53 was stabilized by treatment with DOX ([Fig. 1f](#F1){ref-type="fig"}). p53 repressed the expression of a luciferase gene driven by the genomic fragments containing ME1-RE, ME2-RE1, or ME2-RE3, but not ME2-RE2 ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). p53-mediated repression of certain target genes involves histone deacetylases (HDACs)^[@R9]^. Treatment with trichostatin A (TSA), an inhibitor of HDACs, abrogated p53-mediated repression of *ME1* and *ME2* genes ([Supplementary Fig. 2g](#SD1){ref-type="supplementary-material"}).

*p53* deficiency also led to a strong increase in *ME3* transcript ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). A putative p53 RE is present in the first intron of the *ME3* gene (ME3-RE) ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). p53 bound to the genomic region of ME3-RE in cells ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}) and reduced the expression of a luciferase reporter driven by this RE ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). Given the low abundance of ME3 expression in cell lines that have been tested ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"})^[@R7]^, we focused on ME1 and ME2 in subsequent analyses.

Although ME1 and ME2 have been extensively characterized *in vitro*, there is a paucity of information on their functions in cells. Silencing the expression of *ME1* or particularly *ME2* with small interfering RNA (siRNA) reduced cellular NADPH levels ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). This effect was also observed when a separate set of *ME* siRNAs, as well as *ME* shRNAs, were used ([Supplementary Fig. 5b, c](#SD1){ref-type="supplementary-material"}). In contrast, forced expression of ME1 or especially ME2, or the addition of an ME substrate (dimethyl L-malate), elevated cellular NADPH levels ([Fig. 2b](#F2){ref-type="fig"}, lanes 1--3; [Supplementary Fig. 5d](#SD1){ref-type="supplementary-material"}). To determine whether the effect of MEs is due to their enzymatic activity, we generated two ME1 mutations (ME1^mut1^ and ME1^mut2^) and three ME2 mutations (ME2^mut1^ to ME2^mut3^), each of which exhibited little or no enzymatic activity *in vitro* as well as *in vivo* ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). None of these mutants were able to increase cellular NADPH levels ([Fig. 2b](#F2){ref-type="fig"}, lanes 4--10). Thus, both ME1 and ME2 are required for maintaining cellular NADPH levels through their enzymatic activity, with ME2 having a more profound effect. As previously observed^[@R4]^, knockdown of *p53* led to a significant increase in NADPH levels. This increase was partially reversed through the silencing of *ME1* and was near completely reversed through silencing of *ME2* ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 5a, b](#SD1){ref-type="supplementary-material"}). These results indicate that p53 regulates NADPH metabolism through the suppression of both MEs, particularly ME2.

As NADPH provides reducing equivalents for reductive biosynthesis, we examined the role of MEs in lipid production. MEF cells and 3T3-L1 preadipocytes were cultured with a cocktail that stimulated their differentiation into adipocytes^[@R4],[@R10]^. Triglycerides and total lipid levels in these cells declined when *ME1* or particularly *ME2* was depleted in these cells ([Fig. 2c](#F2){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). In contrast, over-expression of ME1 or especially ME2, but none of the ME1 and ME2 mutants, increased lipid abundance ([Fig. 2d](#F2){ref-type="fig"}). Concordant with previously published data^[@R4]^, we observed a marked increase in lipid levels in *p53*-deficient cells compared to *p53*-proficient cells. *ME1* knockdown partially reversed this increase, while *ME2* knockdown prevented it entirely correlating with its greater influence on cellular NADPH levels ([Fig. 2c](#F2){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). These results suggest that the enhanced lipid accumulation in p53 deficient cells is dependent on the MEs, especially ME2.

Silencing of *ME2*, as well as *ME1*, did not significantly alter NADH levels or the NAD^+^/NADH ratio in IMR90 cells ([Supplementary Fig. 8a, b](#SD1){ref-type="supplementary-material"}), despite that ME2 is characterized as either NADP^+^- or NAD^+^-dependent^[@R5],[@R6]^. NADH can be oxidized by the electron transport chain for ATP production. Silencing of each ME did not significantly alter the abundance of cellular ATP or ADP in IMR90 cells ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}). In U2OS cells silencing of *ME1*, but not *ME2*, reduced NADH levels and increased the NAD^+^/NADH ratio ([Supplementary Fig. 8d, e](#SD1){ref-type="supplementary-material"}). These results are consistent with a cell-type specific role of ME1 and a minimal role of ME2 in maintaining cellular NADH and ATP levels.

Next we investigated the role of ME1 and ME2 in the metabolism of glucose and glutamine. In *p53^−/−^* HCT116 cells silencing of either *ME*, especially *ME2*, strongly reduced glutamine consumption ([Fig. 2e](#F2){ref-type="fig"}), while silencing of either *ME* had a moderate effect on glucose consumption. We extended this analysis by evaluating the rate of glutaminolysis. Depletion of either *ME1* or *ME2* noticeably slowed down glutaminolytic flux ([Fig. 2f](#F2){ref-type="fig"}). These results suggest that both ME1 and ME2 have a major role in glutamine metabolism but a relative minor role in glucose metabolism.

p53 plays a critical role in the induction and maintenance of senescence^[@R1]--[@R3]^. We noticed that in IMR90 cells, a well-established senescence model, silencing of each *ME* by either siRNA or shRNA caused a profound increase in cells expressing senescence-associated β-galactosidase (SA-β-gal) and stopping growth ([Fig. 3a, b](#F3){ref-type="fig"} and [Supplementary Fig. 9a--f](#SD1){ref-type="supplementary-material"}). The induction of senescence in *ME*-knockdown cells was also indicated by the dramatic accumulation the promyelocytic leukemia protein nuclear bodies (PML-NBs)^[@R11],[@R12]^ ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 9g](#SD1){ref-type="supplementary-material"}). Remarkably, even a moderate reduction (20--30%) in either *ME1* or *ME2* strongly elicited senescence ([Supplementary Fig. 10a](#SD1){ref-type="supplementary-material"}). *ME* loss-induced senescence also occurred in tumor cell lines ([Supplementary Fig. 10b, c](#SD1){ref-type="supplementary-material"}). In *p53*-deficient primary and tumor cell lines, senescence decreased markedly, and *ME* depletion lost its ability to induce this phenotype ([Fig. 3b, c](#F3){ref-type="fig"} and [Supplementary Figs. 9b, c, f, g, 10c](#SD1){ref-type="supplementary-material"}). In contrast, *ME* depletion did not cause cell death ([Supplementary Fig. 11a](#SD1){ref-type="supplementary-material"}), and it induced the expression of p53-target genes implicated in senescence^[@R2],[@R13]^ but not apoptosis ([Supplementary Fig. 11b](#SD1){ref-type="supplementary-material"}). These data suggest that down-regulation of *ME* induces senescence via p53.

We next examined the role of MEs in replicative senescence of normal human cells, a p53-regulated process^[@R1],[@R3]^. IMR90 cells were serially passaged in culture until a substantial number of them (\~50%) entered senescence. The expression of ME1 remained at comparable levels at different passages, while the expression of ME2, which stayed unchanged initially, noticeably declined at the late stage ([Fig. 3d](#F3){ref-type="fig"}). To test whether the decline in ME2 contributes to senescence in this setting, we evaluated the replicative capacity of IMR90 cells forced to express ME2. Compared with control cells, ME2-overexpressing cells could be cultured for extended passages with a greatly delayed onset of senescence ([Fig. 3e](#F3){ref-type="fig"} and [Supplementary Fig. 12a](#SD1){ref-type="supplementary-material"}). As ME1 expression was maintained during replicative senescence, we were surprised to observe a delay in senescence when ME1 expression was forced ([Fig. 3e](#F3){ref-type="fig"} and [Supplementary Fig. 12a](#SD1){ref-type="supplementary-material"}). In contrast, forced expression of any of the ME mutants did not delay senescence and instead moderately promoted senescence ([Supplementary Fig. 12b--d](#SD1){ref-type="supplementary-material"}), possibly through a dominant negative effect on the endogenous MEs. These results indicate that both MEs, and especially ME2, are capable of suppressing senescence and suggest that the decline in ME2 may contribute to replicative senescence.

To examine the effect of MEs on other scenarios of p53-regulated senescence, we found that culturing IMR90 cells in medium containing no glutamine resulted in p53-dependent senescence ([Supplementary Fig. 13a](#SD1){ref-type="supplementary-material"}). This senescence could be delayed by over-expression of either ME1 or ME2 ([Supplementary Fig. 13b](#SD1){ref-type="supplementary-material"}), or the addition of the ME substrate malate ([Supplementary Fig. 13c](#SD1){ref-type="supplementary-material"}). In contrast, exogenous ME expression did not influence premature senescence of IMR90 cells induced by the oncogene *Ras^V12^* ([Supplementary Fig. 13d](#SD1){ref-type="supplementary-material"}), which is not dependent on p53 (Ref. [@R14],[@R15]). These results suggest that ME1 and ME2 expression suppress the specific way in which p53 induces senescence.

We investigated the mechanism for ME down-regulation-induced senescence. In IMR90 and U2OS cells where the expression of either *ME1* or *ME2* was silenced by siRNA, even moderately, p53 levels were elevated, accompanied by enhanced phosphorylation of p53 and induction of its target gene *p21* ([Fig. 2a](#F2){ref-type="fig"}, [4a](#F4){ref-type="fig"} and [Supplementary Fig. 5a, 5b, 10a](#SD1){ref-type="supplementary-material"}). In contrast, over-expression of ME1 or ME2 in IMR90 cells substantially reduced p53 levels and activity in late passages ([Fig. 3f](#F3){ref-type="fig"}). Over-expression of ME1 or ME2 also diminished DNA damage-induced p53 activation ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}). These observations suggest a strong role of MEs in the suppression of p53. They also indicate the existence of a positive feedback loop for the p53-ME pathway: a higher p53 level leads to less ME expression, which alleviates the inhibition of MEs on p53, leading to even higher p53 activation.

We examined the mechanism for the regulation of p53 by ME. In unstressed cells, Mdm2-mediated ubiquitination maintains a low basal level of p53 (Ref. [@R2]). When *ME1* was knocked down, the abundance of the Mdm2 protein and mRNA declined markedly ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 15a, b](#SD1){ref-type="supplementary-material"}), suggesting that ME1 down-regulation activates p53 through a reduction in Mdm2 expression. *ME2* knockdown did not significantly affect Mdm2 levels. Instead, it turned on AMP-activated kinase (AMPK) ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 15a, b](#SD1){ref-type="supplementary-material"}), an intracellular energy gauge that activates p53 via phosphorylation^[@R16]^. We tested whether AMPK is required for induction of p53 by ME2 by knocking it down and by comparing *AMPK*-null and -wild-type MEFs. In both situations, loss of *AMPK* prevented *ME2* knockdown from activating p53 ([Fig. 4b](#F4){ref-type="fig"} and [Supplementary Fig. 15c](#SD1){ref-type="supplementary-material"}). Because silencing of *ME2* did not influence cellular ATP levels ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}), we examined other pathways that could activate AMPK in *ME2*-depleted cells and observed a strong increase in reactive oxygen species (ROS) ([Fig. 4c](#F4){ref-type="fig"} and [Supplementary Fig. 16](#SD1){ref-type="supplementary-material"}), correlating with a strong reduction in NADPH levels ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 5a--c](#SD1){ref-type="supplementary-material"}). ROS are a known activator of AMPK^[@R17]^. Treatment with the ROS scavenger N-acetyl cysteine (NAC) blocked AMPK and p53 activation ([Fig. 4d](#F4){ref-type="fig"} and [Supplementary Fig. 17a, b](#SD1){ref-type="supplementary-material"}), abrogated senescence, and restored growth of *ME2*-knockdown cells ([Supplementary Fig. 17c, d](#SD1){ref-type="supplementary-material"}). These results suggest that down-regulation of *ME2* increases ROS levels leading to sequential activation of AMPK and p53 and the induction of senescence. In comparison, depletion of *ME1* increased ROS levels moderately in IMR90 cells and minimally in U2OS cells ([Fig. 4c](#F4){ref-type="fig"} and [Supplementary Fig. 16](#SD1){ref-type="supplementary-material"}), and NAC only slightly affected p53 activation, senescence, and growth arrest in *ME1*-depeleted cells ([Supplementary Fig. 17b--d](#SD1){ref-type="supplementary-material"}).

Previous studies on limited tumor samples suggest that the activity of ME2 is highly elevated in these tumors and correlates with tumor progression^[@R18]--[@R20]^. A survey of public gene expression databases (<http://www.oncomine.org>) showed that both ME1 and ME2 expression was significantly up-regulated in a variety of human cancers ([Supplementary Fig. 18](#SD1){ref-type="supplementary-material"}). We investigated whether MEs could influence tumor cell growth. Depletion of *ME1* or *ME2* in tumor cells, regardless of p53 status, strongly impaired their growth ([Supplementary Fig. 19](#SD1){ref-type="supplementary-material"}), and reduced the number of cells at the S phase of the cell cycle ([Supplementary Fig. 20](#SD1){ref-type="supplementary-material"}). In contrast, over-expression of ME1 or ME2, but none of the ME mutants, enhanced tumor cell growth ([Supplementary Fig. 21](#SD1){ref-type="supplementary-material"}). In a soft agar assay, tumor cells deprived of *ME* expression, unlike their control counterparts, failed to form anchorage-independent colonies ([Supplementary Fig. 22a, b](#SD1){ref-type="supplementary-material"}), while cells transduced with wild-type MEs, but not any of the ME mutants, showed enhanced anchorage-independent growth ([Supplementary Fig. 22c, d](#SD1){ref-type="supplementary-material"}).

To analyze MEs' function in the tumor xenograft model, we injected immunocompromised mice with *p53^+/+^* and *p53^−/−^* HCT116 cells treated with *ME* or control siRNA. *p53^−/−^* HCT116 cells gave rise to tumors that were twice the weight of tumors generated by *p53^+/+^* HCT116 cells. When *ME1* or especially *ME2* was silenced in these cells, the tumor sizes were markedly reduced ([Fig. 4e](#F4){ref-type="fig"} and [Supplementary Fig. 23a, b](#SD1){ref-type="supplementary-material"}). *p53^+/+^* HCT116 tumors devoid of MEs showed extensive senescence and were substantially smaller compared to the corresponding *p53^−/−^* HCT116 tumors ([Supplementary Fig. 23c](#SD1){ref-type="supplementary-material"}). Conversely, over-expression of wild-type ME1 or ME2, not mutant MEs, accelerated the growth of *p53^+/+^* HCT116 tumors ([Fig. 4f](#F4){ref-type="fig"} and [Supplementary Fig. 23d](#SD1){ref-type="supplementary-material"}). These observations indicate that MEs are essential for tumor growth through both p53-dependent and -independent mechanisms.

Although p53 is able to induce a range of anti-proliferative responses, emerging evidence indicates that senescence induction and metabolic regulation are central to its function as a tumor suppressor^[@R13],[@R21]--[@R25]^. Our results demonstrate a positive feedback loop comprising of p53 and MEs that influences p53 activation and links metabolism with the onset of senescence ([Supplementary Fig. 24](#SD1){ref-type="supplementary-material"}). p53 suppresses all *ME* (1, 2, and 3) expression by directly binding to REs within these genes. Together with our recent finding that p53 targets the NADPH producer G6PD through a distinct direct catalytic mechanism^[@R4]^, the current study reveals p53 as a master immediate regulator of cellular NADPH levels. p53 is reciprocally regulated by ME1 and ME2. The marked stabilization of p53 upon *ME1* and *ME2* down-regulation is achieved through different mechanisms, via the decline in the Mdm2 levels and ROS-induced AMPK activation, respectively. These findings support the notion that p53 is a central sentinel for metabolic stresses and coordinates metabolic pathways with cell fate decision.

Mutual regulation of p53 and MEs is likely a major mechanism that modulates cellular senescence in both normal and tumor cells. Even moderate down-regulation of either *ME1* or *ME2* strongly induces p53 activation and senescence, while over-expression of either enzyme delays these processes. Thus, MEs modulate not only the amplitude but also the outcome of p53 activation. p53 is subjected to negative feedback regulation (e.g. the p53-Mdm2 feedback loop) that restrains its activity^[@R2]^. The p53-MEs positive feedback loop is likely important to alleviate the negative feedback regulation so that p53 can accumulate to high levels. This may be particularly relevant in situations where robust and persistent p53 activation is desirable, such as the induction and maintenance of senescence. The involvement of the p53-ME pathway in senescence demonstrates a close link between metabolism and this irreversible fate of the cell.

Methods {#S2}
=======

Antibodies and reagents {#S3}
-----------------------

The antibodies against the following proteins/epitopes were purchased from the indicated sources: ME2, actin, and β-tubulin (Sigma, St Louis, MO); AMPK, phospho-AMPK (Thr172), phospho-p53 (Ser15), and phospho-acetyl-CoA carboxylase (Ser79) (Cell Signaling Technology, Danvers, MA); ME1, p21, and PML (Santa Cruz Biotechnology, Santa Cruz, CA); prohibitin (Thermo Scientific, Hudson, NH); GAPDH (Novus Biologicals, Littleton, CO); p53 (DO-1, Oncogene, Manhasset, NY and Santa Cruz Biotechnology); and Mdm2 (Calbiochem, San Diego, CA and Santa Cruz Biotechnology). The following reagents were purchased from Sigma: dimethyl L-malate, NADP^+^, NAD^+^, doxorubicin, etoposide, trichostatin A (TSA), \[U-^13^C~5~\] glutamine N-acetylcysteine (NAC), insulin, troglitazone, dexamethasone, and isobutylmethylxanthine.

Cell culture and gene knockdown with shRNA and siRNA {#S4}
----------------------------------------------------

Cells were maintained in standard culture conditions without any antibiotic. Expression plasmids for *p53*, *ME1*, and *ME2* shRNA were made in pLKO.1-puro vector. The targeted sequences for human and mouse *p53* are 5'-GACTCCAGTGGTAATCTAC-3' (ref. [@R26]) and 5'-GTACTCTCCTCCCCTCAAT-3' (Ref. [@R27]), respectively. The targeted sequences for human *ME1* and *ME2* are 5'-GGGCATATTGCTTCAGTTC-3' and 5'-GCACGGCTGAAGAAGCATATA-3', respectively. Stable shRNA cell lines were established as previously described^[@R28]^. siRNAs for *ME1*, *ME2*, and *AMPK* were purchased form Invitrogen (Carlsbad, CA). siRNA sequences were AUAACAAUCAGGUAGAAUCUGGUCA (human *ME1*); UAUAGUUGAAGGCUUCAGUAUAUUC (human *ME2*); CCCUGUGGGUAAAUUGGCUCUAUAU (human *ME1*\#2); CCUGACAAGCCAAUUGACAGAUGAA (human *ME2*\#2); CGUUGAAAAUUGCAGUAAA (mouse *ME1*); GGGCACUGAUAACAUGGCACUAUUA (mouse *ME2*); and ACCAUGAUUGAUGAUGAAGCCUUAA (human *AMPK*). siRNAs were transfected into cells using Lipofectamine® RNAiMAX Transfection Agent (Invitrogen).

Semi-quantitative RT--PCR and real time RT-PCR {#S5}
----------------------------------------------

Total RNA was isolated from cells by TRIzol® Reagent (Invitrogen). Two micrograms of RNA for each sample were reversed to cDNA by First-strand cDNA Synthesis System (Marligen Biosciences), and 0.2 µg cDNA were used as a template to perform PCR. The primer pairs for human genes were: *ME1*, 5′-ACAGATAATATTTTCCTCACT-3' and 5′-CTACTGGTCAACTTTGGT-3′; *ME2*, 5′-ATTAGTGACAGTGTTTTCCTA-3' and 5′-CTATTCTGTTATCACAGG-3′; *p21*, 5′-CCGGCGAGGCCGGGATGAG-3' and 5′-CTTCCTCTTGGAGAAGATC-3′; *β-actin*, 5′-GACCTGACTGACTACCTCATGAAGAT-3′ and 5′-GTCACACTTCATGATGGAGTTGAAGG-3′; *p53*, 5′-CACGAGCTGCCCCCAGG-3' and 5′-TCAGTCGACGTCTGAGT-3′. Primer pairs for mouse genes were: *ME1*, 5'-GATGATAAGGTCTTCCTCACC-3' and 5'-TTACTGGTTGACTTTGGTCTGT-3'; *ME2*, 5'-TTCTTAGAAG CTGCAAAGGC-3' and 5'-TCAGTGGGGAAGCTTCTCTT-3'; *p21*, 5'-AACTTCGTCTGGGAGCGC-3' and 5'-TCAGGGTTTTCTCTTGCAGA-3'; *β-actin*, 5'-ACTACATTCAATTCCATC-3' and 5'-CTAGAAGCACTTGCGGTG-3'; *p53*, 5'-GAAGTCCTTTGCCCTGAAC-3' and 5'-CTAGCAGTTTGGGCTTTCC-3'.

All real-time PCR reactions were performed using the 7900HT Fast Real-Time PCR System (Applied Biosystem) and the amplifications were done using the SYBR Green PCR Master Mix (Applied Biosystems). The thermal cycling conditions were: 50 °C for 2 min followed by an initial denaturation step at 95 °C for 10 min, 45 cycles at 95 °C for 15s, 60 °C for 1 min, and a dissociation curve at 95 °C for 15s and 60 °C for 15s. The experiments were carried out in triplicate for each data point. Using this method, we obtained the fold changes in gene expression normalized to an internal control gene.

Cell lysate fractionation and ME activity {#S6}
-----------------------------------------

Cell fractionation was carried out as described^[@R29]^. Cells were homogenized in 20 mM HEPES-KOH (pH 7.5), 10 mM KCl, 1.5 mM MgCl~2~, 1 mM sodium EDTA, 1 mM sodium EGTA, and 1 mM dithiothreitol in the presence of 250 mM sucrose and protease inhibitor cocktail (Roche Diagnostics, Meylan, France). Homogenates were centrifuged at 500 g for 5 min at 4 °C, and the supernatant was collected and centrifuged again at 10,000 g for 20 min to obtain cytosolic and mitochondrial fractions.

ME1 activity was determined using cytosolic extracts as described^[@R30]^. The reaction buffer contained 67 mM triethanolamine, 3.3 mM L-malic acid, 0.3 mM β-NADP^+^, and 5.0 mM manganese chloride. For measuring ME2 activity, mitochondria were purified as described^[@R29]^ and re-suspended in mitochondrial lysis buffer (20 mM MOPS-KOH pH7.4, 250 mM sucrose, 80 mM KCl, 5 mM EDTA, 1 mM PMSF, 1% Triton X-100, and protease inhibitor cocktail) on ice for 30 min by gentle vortexing for 5 s at 5 min intervals. Lysates were centrifuged for 10 min at 14,000 rpm at 4°C. The enzyme reaction mixtures contained 50 mM Tris-HCl, pH7.4, 10 mM MgCl~2~, 0.3 mM NAD^+^, and 3.3 mM L-malic acid. The reactions were started by adding either cytosolic and mitochondrial extracts, and were monitored by absorbance at 340 nm every 5 s for up to 10 min. Background control was run without L-malic acid as substrate. Enzyme activity was determined by subtracting the activity of the background control to each sample. The resulting changes of absorbance versus time were normalized to protein contents, which were determined using the Bio-Rad protein assay.

Analysis of ME gene sequence and chromatin immunoprecipitation (ChIP) assay {#S7}
---------------------------------------------------------------------------

We used the Genomatix Promoter Inspector software (URL: <http://www.genomatix.de>) to search in *ME* genes for potential p53 REs with the consensus sequence 5'-RRRCWWGYYY-(0--13bp spacer)-RRRCWW GYYY-3', where R is a purine, Y a pyrimidine, and W either A or T^[@R8]^. The sequences for the putative p53 REs in *ME* genes are: ME1-RE, 5'-ttacctggttaactaggacttgccc-3'; ME2-RE1, 5'-aggcatgcaccaccatgccc-3'; ME2-RE2, 5'-agaccagtcaaaaacatgtcc-3'; ME2-RE3, 5'-gggcatgatggcacatgcct-3', and ME3-RE, 5'-tgacttggtttggctttcttgtcc-3'.

For ChIP assay, cells were washed with PBS and cross-linked with a 1% formaldehyde solution for 15 min at RT. The cross-linking reaction was stopped by the addition of glycine to 125 mM final concentration. Cell lysates were sonicated to generate DNA fragments with the average size below 1000 bp and followed by immunoprecipitation with indicated antibodies. Bounded DNA fragments were eluted and amplified by PCR. The primer pairs were: ME1-RE: 5'-GCCTTAGTATGTGGATTC-3' and 5'-GGAAAGCGTAGGGAAGGA-3'; ME2-ME1: 5'-GTTGCCCAGGCTGGAGTG-3' and 5'-CTGTAATCCCAGCACTTT-3'; ME2-RE2: 5'-TCAGCACTTTGGGAGG-3' and 5'-GCGACAGAGTCTTGCC-3'; ME2-RE3: 5'-GGCTCAGTGGCTCACG-3' and 5'-GTGCAGTGGCATG-3'; ME3-RE: 5'-GTTGCGATCCCGTGGCTG-3' and 5'-ACCGCAGGTCAGACTGAC-3'; p21: CTGAAAACAGGCAGCCCAAG-3' and 5'-GTGGCTCTGATTGGCTTTCTG-3' ^[@R28]^.

Reporter assay {#S8}
--------------

The DNA fragment containing the potential p53-binding region was amplified by PCR with primers used in the ChIP assay and was cloned into a pGL3-promoter vector (Promega). 293T cells were plated 18 h prior to transfection in 24-well plates and transiently transfected with 450 ng of the reporter plasmid and/or 100 ng of the p53 plasmid using Lipofectamine 2000 (Invitrogen). The Luciferase activity was determined according to the manufacturer\'s instructions (Promega). Transfection efficiency was normalized on the basis of the Renilla luciferase activity.

Measurements of metabolites and lipid accumulation {#S9}
--------------------------------------------------

The levels of NADPH, NADH, NAD^+^, ATP, and ADP in cultured cells were determined using a NADP^+^/NADPH Quantification Kit, NAD^+^/NADH Quantification Kit, ATP assay kit, and ADP assay kit (all from BioVision, Milpitas, CA, USA) respectively, following the manufacturer\'s instructions. Glucose and glutamine consumption was determined using YSI 7100 Multiparameter Bioanalytical System (YSI Life Sciences, Yellow Springs, OH, USA). Triglyceride was measured using a Triglyceride Assay Kit (BioVision). Total lipids were measured using Oil Red O staining^[@R10]^. For this, confluent cells were grown in medium with 10% FBS supplemented with insulin (5 µg/ml), dexamethasone (1 μM), troglitazone (5 μM) and isobutylmethylxanthine (0.5 mM) for 2 days, and in medium supplemented with insulin and rosiglitazone for an additional 5 days. The medium was changed every other day. Cells were then fixed with 4% paraformaldehyde for 30 min at room temperature (RT), washed with dH~2~O and 60% isopropanol, and stained with a filtered Oil Red O work solution at RT. Stain was then removed and cells were washed 4 times in dH~2~O.

Measurement of glutaminolytic flux {#S10}
----------------------------------

Malic enzyme-dependent glutaminolytic flux (ME flux) was determined by labeling the malate pool with ^13^C from \[U-^13^C~5~\] glutamine and monitoring the conversion of malate to pyruvate indirectly by detecting ^13^C-labeled lactate. ^13^C enrichments were determined with gas chromatography-mass spectrometry (GC-MS). We observed that this approach results in approximately 50% ^13^C enrichment and allows for the determination of glutaminolytic flux through malic enzyme with high sensitivity. Cells cultured in 10 cm plates with around 60% confluence were transfected with control, ME1, or ME2 siRNA. Cells were cultured in regular medium for 60 h and in DMEM containing 12 mM glucose, 3 mM \[U-^13^C~5~\] glutamine, and 10% dialyzed fetal bovine serum (Sigma, St. Louis, MO, USA) for an additional 9 h. After medium was removed, cells were immediately quenched with cold 80% methanol. The methanol/cell mass mixtures were centrifuged. The insoluble (protein/lipid) fraction was analyzed for protein content. The soluble fraction was dried under a stream of gaseous nitrogen at 40 °C and silylated with N-tertbutyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA; Regis, Morton Grove, IL, USA). The silylated cell extracts were analyzed with an Agilent 7890A gas chromatograph/5975C mass spectrometer (Agilent, Santa Clara, CA, USA). Mass spectra were quantified with the MSD ChemStation software (Agilent) and corrected for natural abundance contributions from ^13^C, ^[@R29]^Si and ^[@R30]^Si using Isocor ([www.python.org](http://www.python.org))^[@R31]^. The total lactate level was determined with the YSI 7100 Multiparameter Bioanalytical System. The glutaminolytic flux through malic enzymes was calculated from the equation: F~*ME*~= F~*L*~ × (L~m+3~)/(M~m+4~), where F~*ME*~ = malic enzyme flux, F~*L*~ = total lactate flux, L~m+3~= fraction of lactate enriched in all 3 carbons, and M~m+4~= fraction of malate enriched in all 4 carbons.

Measurements of ROS {#S11}
-------------------

ROS levels were determined as described^[@R32]^. Cells were incubated at 37 °C for 30 min in phosphate buffered saline (PBS) containing 10 µM 2',7'-dichlorodihydrofluorescein diacetate (H2-DCFDA, Sigma). Afterwards, the cells were washed twice in PBS, treated with trypsin, and re-suspended in PBS. Fluorescence was immediately measured using a FACScan Flow Cytometer (Becton Dickinson, San Jose, CA).

Senescence-associated β-galactosidase (SA-β-gal) activity {#S12}
---------------------------------------------------------

The SA-β-gal activity in cultured cells was determined using a Senescence Detection Kit (BioVision) following the manufacturer\'s instructions. Percentages of cells that stained positive were calculated by counting 1,000 cells in random fields per cell line.

Immunofluorescence {#S13}
------------------

Cells treated with siRNA for 48 h were washed with 1×PBS and fixed in 4% paraformaldehyde. After being treated with 0.1% Triton X-100, cells were stained using anti-PML antibody followed by Texas-red conjugated anti-mouse IgG antibody, and mounted with 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories). The images were acquired with a confocal microscope. 200 nucleuses were selected randomly and PML-NBs with each nucleus were counted.

Cell proliferation assay {#S14}
------------------------

Cells were treated with siRNAs for 24 h and seeded in 6-well cell culture dishes in triplicates at a density of 20,000 cells/well in 2 ml of medium containing 10% FBS. The medium was changed everyday. Cells were counted and cell number at the indicated time points was determined.

Soft agar assay and xenograft tumor models {#S15}
------------------------------------------

For soft agar assay, cells were suspended in 1 ml of 10% FBS DMEM medium containing a 0.3% agarose and plated on a firm 0.6% agarose base in 6-well plates (5,000 cells/well) as described previously^[@R33]^. Cells were then cultured in a 37°C and 5% CO~2~ incubator for 2 weeks. Images were obtained and colonies were counted under a microscope. Each experiment was done in triplicate. For mouse xenograft experiment, cells (2×10^6^) were injected subcutaneously into the flanks of 4- to 5-week-old athymic Balb-c nu/nu male mice (Taconic Farms, Germantown, NY, USA). Tumor growth was evaluated at 2 weeks post-injection. All animal experiments were performed in accordance with relevant guidelines and regulations and were approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC).
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![p53 represses the expression of MEs\
**a**, ME mRNA and protein expression in U2OS cells stably expressing *p53* shRNA or control shRNA. Relative ME/actin ratios are given. **b, c**, mRNA expression (b), total activity, and protein levels (c) of MEs in *p53*-depleted and control IMR90 cells. Data shown are mean ± SD, n=3. **d**, *ME* expression in *p53^+/+^* and *p53^−/−^* MEFs. **e**, *p53*-depleted and control U2OS cells were treated with increasing amounts of ETO and assayed for ME expression. **f**, *p53^+/+^* HCT116 cells treated with or without DOX (1 µg/ml) were subjected to ChIP assay with anti-p53 (DO-1), a control mouse IgG, or no antibody (−). \*, *p*\<0.05; \*\*, *p*\<0.01; \*\*\*, *p*\<0.001.](nihms420658f1){#F1}

![ME1 and ME2 influence NADPH production, lipid production, and glutaminolysis\
**a, b**, NADPH levels (means ± SD, n=3) in *p53*-depleted and control IMR90 cells transfected with control, *ME1*, or *ME2* siRNA (a), or in IMR90 cells stably over-expressing wild-type MEs, mutant MEs, or vector control. Protein expression is shown below. **c, d**, Triglyceride contents (means ± SD, n=3) in *p53*-depleted and control 3T3-L1 cells transfected with control, *ME1*, or *ME2* siRNA (c), or 3T3-L1 cells stably expressing wild-type MEs, mutant MEs, or vector control (d). mRNA expression is shown below. **e, f**, Effect of *ME1* and *ME2* knockdown in *p53^−/−^* HCT116 cells on glucose and glutamine consumption (means ± SD, n=3) (e), and glutaminolytic flux (f).](nihms420658f2){#F2}

![A role for MEs in suppressing p53-mediated senescence\
**a**, The replicative lifespan (means ± SD, n=3) of IMR90 cells transfected with control, *ME1*, or *ME2* siRNA. **b, c**, IMR90 cells transfected with *ME1*, *ME2*, *p53*, or control siRNA as indicated. Percentages of SA-β-gal-positive cells (means ± SD, n=3) (b) and numbers of PML NBs (c) are shown. See [Supplementary Figs. 9f, g](#SD1){ref-type="supplementary-material"} for representative images. **d**, Percentages of SA-β-gal-positive cells (means ± SD, n=3) (top) and protein expression (bottom) in IMR90 cells at different passages. **e, f**, Replicative lifespan (mean ± SD, n=3) (e), and protein expression (f) of IMR90 cells with and without overexpression of ME1 or ME2. Arrows indicate the onset of senescence (e).](nihms420658f3){#F3}

![Mechanisms of p53 activation induced by ME down-regulation and a role of MEs in tumor growth\
**a**, Effect of *ME1* and *ME2* knockdown on p53 and AMPK activation and Mdm2 expression. ACC: Acetyl-CoA carboxylase. **b**, p53 and AMPK activation in *AMPK^+/+^* and *AMPK^−/−^* MEF cells transfected with control or *ME2* siRNA. **c**, ROS levels in IMR90 cells transfected with *ME1*, *ME2*, or control siRNA. **d**, Effect of NAC on AMPK and p53 activation in IMR90 cells transfected with control siRNA or *ME2* siRNA. **e, f**, Average weights of xenograft tumors (mean ± SD, n=6) generated by *p53^+/+^* and *p53^−/−^* HCT116 cells transfected with *ME1*, *ME2*, or control siRNA (e), or *p53^+/+^* HCT116 cells stably over-expressing wild-type or mutant MEs (f).](nihms420658f4){#F4}
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